Management of chronic heart failure: What do recent clinical trials teach us?

Reviews in Cardiovascular Medicine

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Young, James B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

blockers; ACE inhibitors; Aldosterone receptor blockers; Cardiac resynchronization therapy; Heart failure

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; ENALAPRIL; EPLERENONE; METOPROLOL; MIBEFRADIL; MOXONIDINE; OMAPATRILAT; PLACEBO; VALSARTAN;

ARTICLE; ARTIFICIAL HEART PACEMAKER; CLINICAL PRACTICE; CLINICAL TRIAL; DEFIBRILLATOR; DRUG EFFICACY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PACING; HUMAN; MORTALITY; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 3042628315     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lloyd-Jones DM, Larson MG, Leip EP, et al. Framington Heart Study: lifetime risk for developing congestive heart failure. Circulation. 2002;106:3068-3072.
2. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence and survival with heart failure. N Engl J Med. 2002;347:1397-1402.
3. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2001;104:2996-3007.
4. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol (COMET) randomized controlled trial. Lancet. 2003;362:7-13.
5. Packer M, Fowler MD, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival study (COPERNICUS). Circulation. 2002;106:2194-2199.
6. The CAPRICORN Investigators. Carvedilol post infarction survival control in left ventricular dysfunction (CAPRICORN). Lancet. 2001; 357:1385-1390.
7. The beta blocker evaluation of survival trial investigators. A trial of the beta blocker bucindolol in patients with advanced chronic heart failure. New Engl J Med. 2001;344:1659-1667.
8. Cohn JN, Tognoni G, and the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med. 2001; 345:1667-1675.
9. Pfeffer MA, McMurray JJV, Velasquez EJ, et al. Valsartan, captopril, or both in myocardial infarction. N Engl J Med. 2003;349(20):1893-1906.
10. Swedberg K, Pfeffer MA, Granger CD, et al. for the CHARM Program Investigators. Candesartan in heart failure: assessment of reduction in morbidity and mortality (CHARM) - rationale and design. J Card Fail. 1999;5:276-282.
11. Granger CD, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors (CHARM-Alternative Trial). Lancet. 2003;362:772-776.
12. McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor (CHARM-Added Trial). Lancet. 2003; 362:767-771.
13. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function. (CHARM-Preserved Trial). Lancet. 2003;362:777-781.
14. Pfeffer MA, Swedberg K, Granger CD, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure (CHARM-Overall Programme). Lancet. 2003; 362:759-766.
15. Pitt B, Remme W, Zannad F, et al. Eplerenone: a selected aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
16. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial for the utility in reducing events (OVERTURE). Circulation. 2002;106:920-926.
17. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on dofetilide study group. N Engl J Med. 1999;341:857-865.
18. Levine TB, Bernink PJ, Caspi A, et al. Effect of mibefradil: a T-type calcium channel blocker on morbidity and mortality in moderate to severe congestive heart failure: the MACH-I Study. Mortality assessment in congestive heart failure trial. Circulation. 2000;101:758-764.
19. Swedberg K, Bergh CH, Dickstein K, et al. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. The moxonidine investigators. J Am Coll Cardiol. 2000;35:398-404.
20. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
21. Bardy GH. SCD-HeFt: The sudden cardiac death in heart failure trial. Late breaking clinical trials presentation. American College of Cardiology Scientific Sessions, March 8, 2004, New Orleans, LA.
22. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
23. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE-ICD Trial. JAMA. 2003;289:2685-2694.
24. Bristow MR, Feldman AM, Saxon, LA, et al. Heart failure management using implantable devices for ventricular resynchronization: comparison of medical therapy, pacing, and defibrillation in chronic heart failure (COMPANION Trial). J Card Fail. 2000;6:276-285.